NewAmsterdam Pharma Company N.V. (NAMS)

NASDAQ: NAMS · IEX Real-Time Price · USD

18.90

+0.14 (0.75%)

At close: Jul 19, 2024, 4:00 PM

18.96

+0.06 (0.32%)

Pre-market: Jul 20, 2024, 9:29 AM EDT

NAMS Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	14.09	102.69	0	0
Revenue Growth (YoY)	-	-86.28%	-	-	-
Gross Profit	-	14.09	102.69	0	0
Selling, General & Admin	-	37.63	19.51	6	1.38
Research & Development	-	159.42	86.74	28.97	4.05
Operating Expenses	-	197.06	106.25	34.98	5.43
Operating Income	-	-182.97	-3.56	-34.98	-5.43
Interest Expense / Income	-	0	0.29	0.41	0.34
Other Expense / Income	-	-6.06	18.79	6.4	-0.02
Pretax Income	-	-176.91	-22.63	-41.79	-5.75
Income Tax	-	0.03	0	0	0
Net Income	-	-176.94	-22.63	-41.79	-5.75
Shares Outstanding (Basic)	89	97	78	18	7
Shares Outstanding (Diluted)	-	-	-	18	7
Shares Change	14.92%	25.32%	337.60%	155.70%	-
EPS (Basic)	-	-2.15	-1.19	-3.81	-0.54
EPS (Diluted)	-	-2.15	-1.19	-3.81	-0.54
Free Cash Flow	-	-141.24	10.44	-29.54	-5.98
Free Cash Flow Per Share	-	-1.45	0.13	-1.66	-0.91
Gross Margin	-	100.00%	100.00%	-	-
Operating Margin	-	-1298.56%	-3.46%	-	-
Profit Margin	-	-1255.76%	-22.04%	-	-
Free Cash Flow Margin	-	-1002.43%	10.17%	-	-
EBITDA	-	-176.86	-22.34	-41.37	-5.4
EBITDA Margin	-	-1255.22%	-21.75%	-	-
Depreciation & Amortization	-	0.05	0.01	0.01	0
EBIT	-	-176.91	-22.35	-41.37	-5.41
EBIT Margin	-	-1255.57%	-21.76%	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).